Comparative Pharmacology
Head-to-head clinical analysis: MAXAIR versus THEOCLEAR 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXAIR versus THEOCLEAR 200.
MAXAIR vs THEOCLEAR-200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to bronchodilation. It also acts as an adenosine receptor antagonist and may enhance diaphragmatic contractility.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
Theophylline 200 mg orally every 6 hours (extended-release) or as directed by serum theophylline concentrations. Usual adult target: 400-600 mg/day.
None Documented
None Documented
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Terminal elimination half-life: ~8 hours (range 3–12 hours) in adults; prolonged in hepatic impairment, heart failure, COPD, and neonates. Significantly shorter in smokers (4–6 hours).
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Renal: ~10% unchanged; Hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination; metabolites (caffeine, 3-methylxanthine, 1-methyluric acid) excreted renally. Fecal excretion negligible.
Category C
Category C
Bronchodilator
Bronchodilator